ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · IEX Real-Time Price · USD
5.87
+0.35 (6.34%)
At close: May 3, 2024, 4:00 PM
6.05
+0.18 (3.07%)
After-hours: May 3, 2024, 5:41 PM EDT
ClearPoint Neuro Revenue
In the year 2023, ClearPoint Neuro had annual revenue of $23.96M with 16.56% growth. Revenue in the quarter ending December 31, 2023 was $6.81M with 31.62% year-over-year growth.
Revenue (ttm)
$23.96M
Revenue Growth
+16.56%
P/S Ratio
6.61
Revenue / Employee
$223,879
Employees
107
Market Cap
158.35M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
Dec 31, 2019 | 11.22M | 3.86M | 52.54% |
Dec 31, 2018 | 7.35M | -26.26K | -0.36% |
Dec 31, 2017 | 7.38M | 1.63M | 28.35% |
Dec 31, 2016 | 5.75M | 1.16M | 25.15% |
Dec 31, 2015 | 4.59M | 989.71K | 27.46% |
Dec 31, 2014 | 3.60M | -326.09K | -8.30% |
Dec 31, 2013 | 3.93M | -1.13M | -22.29% |
Dec 31, 2012 | 5.06M | 1.24M | 32.48% |
Dec 31, 2011 | 3.82M | 1.15M | 43.03% |
Dec 31, 2010 | 2.67M | 69.45K | 2.67% |
Dec 31, 2009 | 2.60M | 650.00K | 33.33% |
Dec 31, 2008 | 1.95M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Outset Medical | 130.38M |
InfuSystem Holdings | 125.79M |
Electromed | 51.69M |
Repare Therapeutics | 51.13M |
Biodesix | 49.09M |
Seer, Inc. | 16.66M |
Cardiff Oncology | 610.00K |
CLPT News
- 3 days ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT) - PRNewsWire
- 19 days ago - ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations - GlobeNewsWire
- 6 weeks ago - ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency - GlobeNewsWire
- 7 weeks ago - ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results - GlobeNewsWire
- 2 months ago - ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024 - GlobeNewsWire
- 2 months ago - ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock - GlobeNewsWire
- 2 months ago - ClearPoint Neuro Launches Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo - GlobeNewsWire